Antifungal prophylaxis following reduced-intensity stem cell transplantation.

about

Antifungal prophylaxis following reduced-intensity stem cell transplantation.

Item

http://www.wikidata.org/entity/Q36658236

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Antifungal prophylaxis following reduced-intensity stem cell transplantation.

@ast

Antifungal prophylaxis following reduced-intensity stem cell transplantation.

@en

type

Item

label

Antifungal prophylaxis following reduced-intensity stem cell transplantation.

@ast

Antifungal prophylaxis following reduced-intensity stem cell transplantation.

@en

prefLabel

Antifungal prophylaxis following reduced-intensity stem cell transplantation.

@ast

Antifungal prophylaxis following reduced-intensity stem cell transplantation.

@en

P1476

Antifungal prophylaxis following reduced-intensity stem cell transplantation.

@en

P2093

Kami M

http://www.w3.org/2001/XMLSchema#string

Murashige N

http://www.w3.org/2001/XMLSchema#string

Narimatsu H

http://www.w3.org/2001/XMLSchema#string

Tanaka Y

http://www.w3.org/2001/XMLSchema#string

P2860

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis

In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

Clinical relevance of genetic polymorphisms in the human CYP2C subfamily

In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.

P304

190-202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1399-3062.2006.00152.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17116132

http://www.w3.org/2001/XMLSchema#string